Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B.

Détails

ID Serval
serval:BIB_8D7A7CF7223F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B.
Périodique
Journal of Clinical Virology
Auteur(s)
Farnik H., Lange C.M., Hofmann W.P., Berger A., Allwinn R., Welker M.W., Trojan J., Sarrazin C., Herrmann E., Zeuzem S., Kronenberger B.
ISSN
1873-5967 (Electronic)
ISSN-L
1386-6532
Statut éditorial
Publié
Date de publication
2011
Volume
52
Numéro
3
Pages
204-209
Langue
anglais
Résumé
Background: Reduction of necroinflammatory activity is a major goal of antiviral therapy of patients with chronic hepatitis B. Serum ALT does not detect all forms of cell death.Objectives: To analyze dynamics of novel serum cell death markers for apoptosis and necrosis in association with virologic response to nucleos(t)ide (Nuc) analogue treatment.Study design: Quantification of the M30-apoptosis neoepitope and the cytokeratin-18 (M65-necrosis) serum levels before and during treatment of patients with chronic hepatitis B with Nuc (n = 26).Results: Before treatment, M30-apoptotic activity was significantly correlated with M65-necrosis and fibrosis but not with serum ALT. During therapy with Nucs, cell death parameters M30-apoptosis, M65-necrosis, and ALT declined in association with virologic response. The most frequent cell death pattern was simultaneous decline of ALT and M30-apoptosis which occurred more frequently in patients with HBs-Antigen decline than in patients with HBs-Antigen increase during treatment (87.5% vs. 40.0%; p = 0.024). ALT decline in association with increase of M30 apoptosis was frequent in patients with HBs-Antigen increase during treatment (36.3%) but was not observed in patients with HBs-Antigen decline during treatment.Conclusion: Decline of cell death parameters in association with decline of HBV-DNA and HBs-Antigen indicates a reduction in overall cell death activity during Nuc treatment supporting the concept that response to Nuc therapy reduces necroinflammatory activity and progression of liver disease. (C) 2011 Elsevier B. V. All rights reserved.
Pubmed
Web of science
Création de la notice
01/12/2011 15:09
Dernière modification de la notice
03/03/2018 19:16
Données d'usage